100 Rodolphe Street
Tel: (800) 682-2666
World leader in the field of in vitro diagnostics for over 55 years, bioMérieux conceives, develops, produces and markets diagnostics solutions (systems, reagents, software and services) intended for clinical and industrial applications, which determine the origin of a disease or a contamination to improve the health of patients and insure consumer safety.
bioMérieux is present in 43 countries and servces more than 160 countries with the support of a large network of distributors. Its corporate headquarters are located in Marcy l'Etoile, near Lyon, in France.
Joining bioMérieux, is choosing to join an innovative company with a long term vision, committed to the service of public health and carried out with a humanistic corporate culture.
We look for candidates whose motivation is to invest in themselves, in the projects of the future, and to participate in a collective adventure led by a pioneering spirit.
We have the commitment to offer our collaborators a working environment which encourages team spirit, with priority given to training and development with international career opportunities.
Our Group offers numerous possibilities: so come and join the 11,200 bioMérieux employees who have already identified with these values!
75 articles with bioMerieux
Mérieux NutriSciences and bioMérieux Issue the Results of a Food Safety Survey for the World Food Safety Day
For this inaugural World Food Safety Day, Mérieux NutriSciences and bioMérieux conducted an international consumer survey1 to better understand consumer perception and behaviors towards food safety in four countries: the United States, China, France and India.
Philips Healthcare is the Quarter 2 Featured Supplier
The agreement highlights the two companies’ shared focus on antibiotic stewardship and preventing sepsis in hospital care settings by delivering better solutions for healthcare providers to fight infections and their often-deadly complications.
bioMerieux: FDA Clears Test To Help Manage Antibiotic Treatment For Lower Respiratory Tract Infections And Sepsis
Quanterix Release: Company Announces Significant Advancements To Strategic Partnership With bioMerieux
bioMerieux Warns About Potential Inaccurate Test Results When Using NucliSENS easyMAG Magnetic Silica
bioMerieux Submits 510(K) Application To The bioMerieux For BacT/ALERT VIRTUO Next Generation Automated Blood Culture System
bioMerieux, Inc. And Illumina Announce The Launch Of bioMérieux Episeq, A Revolutionary Next-Generation Sequencing Service For Epidemiological Monitoring Of Bacterial Infections
ATCC and bioMerieux, Inc. Collaborate To Deliver Accurate Identification Of Industrial Microorganisms
bioMerieux, Inc.'s THxID®-BRAF Test For Detection Of 2 BRAF Mutations V600E And V600K In Late-Stage Metastatic Melanoma Adopted By Clarient, Inc., A GE Healthcare Company
Thermo Fisher Scientific and bioMerieux, Inc. Renew Partnership for Improved Detection of Sepsis Using PCT Biomarker